腹腔镜子宫切除术后非阿片类与常规阿片类处方的随机对照非劣效试验
本研究在学术医疗中心开展非劣效随机对照试验,纳入因良性指征行腹腔镜或机器人子宫切除的成年患者,1:1随机接受非阿片类方案(对乙酰氨基酚+布洛芬)或标准阿片类方案(对乙酰氨基酚+布洛芬+12片5mg羟考酮)。主要结局为术后第1天和第7天NRS-11疼痛评分,非劣效界值1.5分。结果显示两组疼痛评分差异均为-1.0(97.5%CI -2.2至0.2),符合非劣效标准,且非阿片组羟考酮消耗中位数为0片。
要点
- 非阿片类术后镇痛方案在疼痛评分上非劣效于常规阿片类处方。
- 非阿片组术后7天内羟考酮消耗中位数为0片,阿片组为1片。
- 两组患者对疼痛控制的满意度均较高。
核心结论
- 微创子宫切除术后非阿片类疼痛管理非劣效于常规阿片类处方,并大幅减少阿片类药物使用,支持在该人群中采用阿片节约策略。
研究设计与样本
- 非劣效随机对照试验,2023年1月至2024年1月在学术医疗中心开展。
- 纳入因良性指征行腹腔镜或机器人子宫切除的成年患者(≥18岁),1:1随机分组。
- 计划样本量60例,预设非劣效界值为NRS-11评分1.5分。
- 筛查221例合格患者,71例签署知情同意,最终64例纳入分析(阿片组33例,非阿片组31例)。
主要发现
- 术后第1天平均疼痛评分:非阿片组4.0 vs 阿片组5.0,差异-1.0(97.5%CI -2.2至0.2)。
- 术后第7天平均疼痛评分:非阿片组2.1 vs 阿片组3.1,差异-1.0(97.5%CI -2.2至0.2)。
- 两组疼痛评分差异均符合非劣效标准,且两组疼痛控制满意度均较高。
- 术后第7天羟考酮消耗中位数:阿片组1片,非阿片组0片。
关键数值与推荐
- 非阿片类方案为对乙酰氨基酚联合布洛芬;标准阿片类方案为对乙酰氨基酚、布洛芬联合12片5mg羟考酮。
- 非阿片组若疼痛控制不佳可请求阿片类药物。
- 主要结局为非劣效设计,非劣效界值为NRS-11评分1.5分。
临床怎么用
- 微创子宫切除术后可优先采用非阿片类多模式镇痛方案,减少常规阿片类处方。
- 非阿片方案下应保留按需阿片类药物补救通道,以应对疼痛控制不佳的情况。
局限性
- 样本量较小(最终分析64例),筛查221例仅71例签署知情同意。
- 单中心研究,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether prescribing a nonopioid postoperative pain regimen after minimally invasive hysterectomy for benign indications is noninferior to prescribing routine opioids with respect to pain scores and patient satisfaction. METHODS: We conducted a noninferiority randomized controlled trial at an academic medical center from January 2023 to January 2024. Adult patients (age 18 years and older) undergoing laparoscopic or robotic hysterectomy for benign indications were randomized 1:1 to a nonopioid regimen (acetaminophen and ibuprofen) or a standard opioid regimen (acetaminophen, ibuprofen, and 12 5-mg oxycodone tablets). Participants in the nonopioid arm could request opioids if pain was inadequately controlled. Primary outcomes were pain scores on postoperative days 1 and 7, measured using the NRS-11 (11-point Numeric Rating Scale). Secondary outcomes included satisfaction with pain control and opioid consumption. The planned sample size of 60 participants was adequate for a predefined noninferiority margin of 1.5 points on the NRS-11. RESULTS: Of 221 eligible patients screened, 71 consented; 64 were included in the final analysis (33 opioid, 31 nonopioid). Mean pain scores were similar between groups on postoperative day 1 (4.0 vs 5.0; difference -1.0; 97.5% CI, -2.2 to 0.2) and postoperative day 7 (2.1 vs 3.1; difference -1.0; 97.5% CI, -2.2 to 0.2), which met the criteria for noninferiority. Satisfaction with pain control was high in both groups. By postoperative day 7, median oxycodone consumption was 1 tablet in the opioid group and 0 in the nonopioid group. CONCLUSION: Nonopioid postoperative pain management after minimally invasive hysterectomy is noninferior to routine opioid prescribing and substantially reduces opioid use, supporting opioid-sparing strategies in this population. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov , NCT05548582.
引用
- Leaf MC, Wainger J, Frost A, et al. Evaluating Routine Opioid Compared With Nonopioid Prescribing After Laparoscopic Hysterectomy: A Randomized Controlled Trial. Obstet Gynecol. 2026. PMID: 42535875. doi:10.1097/AOG.0000000000006378
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。